4D Molecular Therapeutics, Inc.

FDMT Nasdaq SEC CIK 1650648
Follow 4D Molecular Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $4.1M +4505.6% vs same quarter last year
Net income −$78.1M −37.2% vs same quarter last year
EPS, diluted −$1.08 −6.9% vs same quarter last year
Operating cash flow −$56.7M −22% vs same quarter last year
Revenue by quarter
$1K
$14K
$15K
$90K
$85.1M
$3M
$3.8M
$4.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$85.2M−$140.1M
FY24$37K−$160.9M
FY23$20.7M−$100.8M
FY22$3.1M−$107.5M
FY21$18M−$71.3M
FY20$13.4M−$56.7M
FY19$7M−$49.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600000%−400000%−200000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−187.2%−164.4%
FY24−507678.4%−434778.4%
FY23−544.6%−486.6%
FY22−3516.5%−3435.4%
FY21−395.5%−395.4%
FY20−424%−424.3%
FY19−729.4%−708.4%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$109.6M
FY24−$138.4M
FY23−$78.6M
FY22−$98.2M
FY21−$78.2M
FY20−$51.9M
FY19−$39.9M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • 4D Molecular Therapeutics
  • Healthcare median
−600000%−400000%−200000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
Year4D Molecular TherapeuticsHealthcare median
FY25−164.4%−30.6%
FY24−434778.4%−47%
FY23−486.6%−58%
FY22−3435.4%−80.4%
FY21−395.4%−71.8%
FY20−424.3%−62.2%
FY19−708.4%−46.2%
FY18-−49.6%